Patents by Inventor Chungen Liang

Chungen Liang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200385387
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 10, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20200369664
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salts, enantiomers or diastereomers thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen LIANG, Jianping WANG, Hongying YUN, Kun MIAO
  • Patent number: 10752630
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 25, 2020
    Assignee: HOFMANN LA-ROCHE INC.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20200109144
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 2, 2019
    Publication date: April 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 10399983
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: September 3, 2019
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Publication number: 20190256515
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 29, 2019
    Publication date: August 22, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Patent number: 10336751
    Abstract: The invention provides novel compounds having the general formula: wherein R1 to R7 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 2, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Zhanling Cheng, Xingchun Han, Chungen Liang, Song Yang
  • Patent number: 10233184
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: March 19, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Patent number: 10189838
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds for the treatment and prophylaxis of respiratory syncytial virus infection.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: January 29, 2019
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lisha Wang, Lu Gao, Mengwei Huang, Lei Guo, Chungen Liang, Wei Zhu, Song Feng, Xiufang Zheng, Weixing Zhang, Guolong Wu, Baoxia Wang, Hongying Yun
  • Publication number: 20180134705
    Abstract: The invention provides novel compounds having the general formula: wherein R1 to R7 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 17, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhanling CHENG, Xingchun HAN, Chungen LIANG, Song YANG
  • Patent number: 9949966
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5 and R6 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: April 24, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Xingchun Han, Hassan Javanbakht, Min Jiang, Chungen Liang, Jianping Wang, Yongguang Wang, Zhanguo Wang, Robert James Weikert, Song Yang, Chengang Zhou
  • Publication number: 20180072730
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Hongying Yun, Xiufang Zheng, Jianping Wang, Kun Miao, Bo Zhang
  • Publication number: 20180072726
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, W1, W2, W3, A and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 16, 2015
    Publication date: March 15, 2018
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Lisha WANG, Lu GAO, Mengwei HUANG, Lei GUO, Chungen LIANG, Wei ZHU, Song FENG, Xiufang ZHENG, Weixing ZHANG, Guolong WU, Baoxia WANG, Hongying YUN
  • Patent number: 9902701
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: February 27, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Song Yang, Chungen Liang, Jianping Wang, Song Pan
  • Patent number: 9790213
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3 and Q are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: October 17, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lu Gao, Chungen Liang, Lisha Wang, Hongying Yun
  • Publication number: 20170275286
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: June 13, 2017
    Publication date: September 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Patent number: 9708325
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: July 18, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng
  • Publication number: 20170157133
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, X and a are as described in the description and in the claims, as well as or pharmaceutically acceptable salts thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: February 14, 2017
    Publication date: June 8, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Song Yang, Chungen Liang, Jianping Wang, Song Pan
  • Patent number: 9670211
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, W and X are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 6, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lu Gao, Lei Guo, Chungen Liang, Baoxia Wang, Lisha Wang, Hongying Yun, Weixing Zhang, Xiufang Zheng
  • Publication number: 20160326177
    Abstract: The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Chungen Liang, Jianping Wang, Kun Miao, Hongying Yun, Xiufang Zheng